MAIA Biotechnology, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +14.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.11 | $-0.13 | -18.2% | Miss | |
| Q1 FY26 | $-0.18 | $-0.14 | +22.2% | Beat | |
| Q4 FY25 | $-0.13 | $-0.08 | +38.5% | Beat |
Back to MAIA overview · MAIA holders · MAIA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.